GW-0742

GW-0742 is a high-affinity synthetic agonist of peroxisome proliferator-activated receptor δ (PPARδ) — a nuclear receptor that, when liganded, reprograms cellular metabolism toward fatty-acid oxidation, mitochondrial biogenesis, and oxidative-fiber dominance. Practically, this is the same transcriptional program that endurance training switches on. GW-0742 turns it on pharmacologically.

PPARδ Selectivity and Receptor Binding#

GW-0742 binds the PPARδ ligand-binding domain with low-nanomolar affinity and shows roughly 1,000-fold selectivity over the PPARα and PPARγ subtypes. That selectivity matters: PPARα agonism (fibrates) tilts the lipid program toward the liver, and PPARγ agonism (thiazolidinediones) drives adipogenesis and water retention. GW-0742 sidesteps both and routes the signal almost exclusively through the δ isoform expressed in skeletal muscle, heart, and vasculature.

"GW0742 has an EC50 of 1 nM for human PPARδ, showing >1000-fold selectivity over PPARα and PPARγ subtypes." — Sznaidman ML et al., Bioorganic & Medicinal Chemistry Letters (2003)

Off-target profiling at supratherapeutic concentrations shows only weak interaction with a handful of other nuclear receptors, including the vitamin D receptor — clinically irrelevant at protocol doses but worth flagging for anyone running it at the top of the ladder.

"GW0742 was found to interact weakly with several nuclear receptors at concentrations much higher than needed to activate PPARδ." — Nandhikonda P et al., Biochemistry (2013)

Fatty-Acid Oxidation and Substrate Switching#

On ligand binding, PPARδ heterodimerizes with RXR and drives transcription of the core fatty-acid-oxidation cassette: CPT1, PDK4, UCP3, ANGPTL4, and downstream mitochondrial respiratory-chain components. The functional outcome is a substrate shift — muscle preferentially burns fatty acids and spares glycogen during submaximal work. For the recomp-focused user in a deficit, this biases the deficit toward fat-mass loss; for the endurance-focused user, it pushes the lactate threshold up and delays glycogen depletion. This is the mechanism behind the "another set in the tank" effect users describe.

Oxidative Fiber Remodeling and the Exercise-Mimetic Effect#

The signature finding of the class is muscle-fiber remodeling. PPARδ activation upregulates PGC-1α and AMPK signaling — the same axis hit by training and by metformin — and increases the proportion of type I oxidative myofibers. Critically, the effect is synergistic with training, not a substitute for it.

"PPARδ agonist and exercise training independently increased the number of oxidative myofibers, and in combination, they synergistically enhanced endurance exercise performance." — Narkar VA et al., Cell (2008)

This is why GW-0742 stacks best with conditioning blocks, GPP phases, and cardio-heavy cuts rather than pure hypertrophy work. The oxidative-fiber bias does nothing for one-rep max and is not a strength compound — the muscle-growth and strength scores on this profile are zero for a reason.

Cardiovascular and Vascular Effects#

PPARδ is highly expressed in vascular smooth muscle and cardiomyocytes. Agonism relaxes pulmonary vasculature, improves endothelial function, and protects the right heart under hypoxic stress — relevant context for users stacking GW-0742 with harsh-on-cardiovascular AAS (trenbolone, high-dose orals) where afterload and vascular resistance are already elevated.

"Oral GW0742 treatment significantly reduced right ventricular systolic pressure, cardiac hypertrophy, and improved pulmonary artery relaxation in hypoxic rats." — Kojonazarov B et al., Pulmonary Circulation (2013)

The same transcriptional program drives the favorable lipid signal the community reports on cycle: modest HDL increases and triglyceride reductions, the inverse of what oral AAS do to a panel. This is the basis for the "lipid-rescue" use case.

Pro-Survival Signaling — the Carcinogenicity Caveat#

The same machinery that makes PPARδ activation useful — catalase upregulation, AKT activation, enhanced survival under metabolic stress — is also the machinery that lets malignant cells survive conditions that would otherwise kill them. This is not a hypothetical concern; it is the mechanism that ended the GW-501516 clinical program.

"Activation of PPARδ by GW0742 or GW501516 increased catalase expression and promoted the survival of breast cancer cells during metabolic stress." — Wang X et al., Oncogenesis (2016)

"PPARβ/δ agonists such as GW0742 have shown context-dependent pro-tumorigenic and pro-survival effects in preclinical cancer models." — Wagner N, Wagner KD, Cells (2020)

The practical reading: PPARδ agonism is broadly pro-survival, which is the point in healthy muscle and vasculature and the problem in tissue that has already gone wrong. Anyone with a personal or first-degree-family history of colorectal, hepatic, or breast malignancy should treat this class as contraindicated. For everyone else, the standard 8-week-on / 4-week-off cycling pattern exists specifically because of this signal — not because of HPTA recovery, which is not a factor with this compound.

Common (most users)#

• Mild GI upset — occasional nausea or loose stools, usually in the first week. Administered with a small meal containing fat (the compound is highly lipophilic and absorption benefits from it); splitting the dose AM/PM is rarely needed but eliminates the issue when it occurs.
• Headache — low-grade, typically resolves within 5–7 days. Hydration and electrolyte support (sodium + magnesium) handle it; persistent headache past two weeks warrants dropping the dose by 25–30%.
• Transient fatigue in the first 3–5 days — the metabolic shift toward fatty-acid oxidation takes ~1 week to fully express. Carbohydrate intake around training stays unchanged during this window; the "flat" sensation resolves as mitochondrial adaptation catches up.
• Sleep changes — usually improvements (deeper sleep on training days), occasionally lighter sleep if dosed late. Morning administration, 30–60 minutes pre-training, sidesteps this entirely.

Uncommon (dose-dependent or individual)#

• Lipid panel shifts — generally favorable (HDL up, triglycerides down) consistent with PPARδ activation, but a minority of users report mildly elevated LDL on stacks with harsh orals. Baseline and 4-week lipid panels catch this; the compound itself is not the driver in those cases.
• Mildly elevated liver enzymes on AAS stacks — GW-0742 is not hepatotoxic in rodent studies, but ALT/AST should be tracked when stacked with 17α-alkylated orals, since the compound increases hepatic fatty-acid flux. Dropping the oral, not the GW-0742, is the typical correction.
• Receptor desensitization at high doses or long cycles — chronic high-dose PPARδ activation downregulates the receptor in rodent studies. The practical signal: diminishing endurance returns past week 10. The protocol calls for an 8–12 week ceiling with a 4-week off-period rather than continuous administration.
• "Flat" muscle appearance in deep deficits — the substrate shift toward fat oxidation can blunt glycogen storage in lean users running aggressive deficits. Backing off to 5 mg/day or adding a refeed day restores fullness.

Rare but serious#

• Pro-survival signaling in occult malignancy — Wang et al. demonstrated that PPARδ activation lets breast cancer cells survive metabolic stress via catalase upregulation, and Wagner & Wagner's review documents context-dependent pro-tumorigenic effects across cancer types:

"PPARβ/δ agonists such as GW0742 have shown context-dependent pro-tumorigenic and pro-survival effects in preclinical cancer models." — Wagner & Wagner, Cells (2020)

"Activation of PPARδ by GW0742 or GW501516 increased catalase expression and promoted the survival of breast cancer cells during metabolic stress." — Wang et al., Oncogenesis (2016)

This is the carcinogenicity signal that ended GSK's GW-501516 program. It is not a guaranteed cycle-length cancer; it is a real mechanism that makes PPARδ agonists categorically unsuitable for anyone with malignancy risk factors. Unexplained weight loss, persistent abdominal pain, rectal bleeding, or new palpable lumps during a cycle warrant immediate cessation and workup.

• Off-target nuclear receptor activity — Nandhikonda et al. documented weak interaction with the vitamin D receptor and several other nuclear receptors at supratherapeutic concentrations. Not relevant at community doses, but a reason not to push past 15 mg/day chasing dose-response effects that aren't there.

• Neuronal cytotoxicity at prolonged exposure — Smith et al. (2004) found GW-0742 neuroprotective in short-exposure cerebellar neuron cultures but cytotoxic to the same cells at 48-hour exposure. The dose/duration signal is the reason 8 weeks is the modal cycle length and 12 weeks the ceiling.

Hard contraindications#

• Personal history of colorectal, hepatic, or breast malignancy — the pro-survival mechanism is the entire problem. Do not run.
• First-degree family history of GI or hepatic cancer — same logic; the risk multiplier is real.
• Active malignancy of any kind — absolute contraindication.
• Pregnancy and lactation — PPARδ is developmentally active and no safety data exists. Hard line.
• Competitive drug-tested sport — GW-0742 is named explicitly on the WADA Prohibited List (S4.5 Metabolic Modulators), prohibited at all times. The sulfone metabolite is detectable in urine for an extended window and the parent compound incorporates into hair. There is no defensible "out of season" use for tested athletes.
• Active or recent investigation of unexplained GI bleeding, hepatic lesions, or breast masses — finish the workup before any PPARδ ligand enters the picture.

Gender, fertility, and PCT considerations#

GW-0742 is non-hormonal and non-suppressive. It does not bind the androgen receptor, does not aromatize, and does not affect the HPTA. No PCT is required after a stand-alone GW-0742 cycle, and dosing applies uniformly across sexes — there is no virilization risk and no hormonal rationale for differentiated male/female protocols.

For women: pregnancy and lactation are the only hard contraindications. PPARδ is developmentally active and no human safety data exists in this context. Contraception should be in place throughout the cycle for any user with pregnancy potential.

For men: no fertility impact, no testicular atrophy, no estrogen management required. The compound is frequently added to AAS cycles for lipid and cardiovascular support precisely because it adds zero hormonal complexity to the stack — the side-effect ledger to manage is metabolic and oncologic, not endocrine.